# HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)

> **NCT00192660** · PHASE4 · COMPLETED · sponsor: **Kirby Institute** · enrollment: 80 (actual)

## Conditions studied

- HIV-Associated Lipodystrophy Syndrome
- Cardiovascular Disease

## Interventions

- **DRUG:** Lamivudine
- **DRUG:** Stavudine
- **DRUG:** Didanosine
- **DRUG:** Zidovudine
- **DRUG:** Tenofovir
- **DRUG:** Abacavir
- **DRUG:** Efavirenz (EFV)
- **DRUG:** Nevirapine
- **DRUG:** Indinavir
- **DRUG:** Saquinavir
- **DRUG:** Amprenavir
- **DRUG:** Ritonavir
- **DRUG:** Nelfinavir
- **DRUG:** Tipranavir
- **DRUG:** enfuvirtide (T20)

## Key facts

- **NCT ID:** NCT00192660
- **Lead sponsor:** Kirby Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2006-10
- **Final completion:** 2007-12
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2012-04-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00192660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00192660, "HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00192660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*